![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Vnitř. Lék., 48, 2002, No. 3, p. 248-254 |
Antifungal Prophylaxis
in Oncological Patients with a Respect to Toxicity of Antimycotic Drugs Doubek M., Mayer J., Horký D., Doubek J., Ráčil Z., Vorlíček J. Interní hematoonkologická klinika Fakultní nemocnice Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. Ústav histologie a embryologie Lékařské fakulty Masarykovy univerzity, Brno, přednosta prof. MUDr. Drahomír Horký, DrSc. Ústav normální a patologické fyziologie Veterinární a farmaceutické univerzity, Brno, přednosta doc. MVDr. Jaroslav Doubek, CSc. |
|
Summary: Profound and prolonged neutropenia following chemotherapy is a major risk factor for systemic
fungal infections. It is still unclear how effective the various measures that are currently being
used are in preventing serious fungal infection. Although a number of studies have been publish-
ed on antifungal prophylaxis in neutropenic patients, there are a lot of conflicting data. At the
present time, it seems that antifungal prophylaxis is more a matter of faith rather than science.
The prophylactic use of fluconazole or itraconazole may reduce the incidence of systemic fungal
infections in high-risk patient groups, mainly in patients with haematological malignancies. The
antifungals currently used for prophylaxis in immunocompromised patients, and the toxicity of
the antifungals are reviewed.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |